Athero-Blocker – New peptides for the prevention and treatment of atherosclerosis
Scientists at the RWTH Aachen have identified new
peptides which can be used for the prevention of atherosclerosis or in the treatment of related cardiovascular diseases. It is known that adherent activated platelets secrete chemoattractants, such as the chemokines PF4 and RANTES, which are responsible for monocyterecruitment. Receptor-blocking experiments and studies with knock-out mice indicated that RANTES signals contribute to intimal hyperplasia and macrophage infiltration in models of restenosis. Moreover, it plays an important role in the initiation and maintenance of atherosclerosis. Athero-Blocker is specifically targeting the interaction between the chemokines RANTES and PF4. It can thereby abrogate the proatherogenic enhancement of monocyte recruitment caused by this interaction. A good efficacy of Athero-Blocker has been demonstrated in in vitro experiments, in cell based test systems and in mouse models in vivo.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
Single-Celled Heroes: Foraminifera’s Power to Combat Ocean Phosphate Pollution
So-called foraminifera are found in all the world’s oceans. Now an international study led by the University of Hamburg has shown that the microorganisms, most of which bear shells, absorb…
Humans vs Machines—Who’s Better at Recognizing Speech?
Are humans or machines better at recognizing speech? A new study shows that in noisy conditions, current automatic speech recognition (ASR) systems achieve remarkable accuracy and sometimes even surpass human…
Not Lost in Translation: AI Increases Sign Language Recognition Accuracy
Additional data can help differentiate subtle gestures, hand positions, facial expressions The Complexity of Sign Languages Sign languages have been developed by nations around the world to fit the local…